Collaboration comes after renewed focus on key therapeutic areas of immunology and oncology
News
Granular boosts mast cell disease programme
Therapy candidates chosen for lead projects targeting mast cell driven diseases
AlzeCure reveals positive NeuroRestore ACD856 data
Therapy is a positive modulator and has demonstrated that it can improve learning and memory
Clinical trial transformation funds for Aberdeen scientist
Dr Beatriz Goulao receives more than £500,000 to make trials more patient-focused
Netris pancreatic cancer study doses first patient
Company’s candidate NP137 combined with mFOLFIRINOX will be researched during vital trials
iOnctura’s roginolisib awarded Innovation Passport
MHRA designation involves entry into innovative licensing and access pathway
EnteroBiotix begins phase 2 study of candidate drug EBX-102
Clinical trial involves patients with liver cirrhosis and hepatic encephalopathy
PMGroup announces launch of new recruitment platform PharmaRole
The platform makes it easy to find and apply for jobs in the pharmaceutical and life sciences industry
SolasCure announces pivotal financing round for hydrogel
Company is developing a therapy containing an enzyme cloned from medical maggots
CSL’s Hemgenix receives MHRA authorisation
Treatment is the only single infusion gene therapy for the treatment of severe haemophilia B
2023 PM Society Awards – Winners Announced
21GRAMS takes four Golds plus Best in Show AstraZeneca tops the pharma leader board
Destiny releases pivotal phase 2 data involving XF-73 nasal gel
Study shows significant reduction of nasal S. aureus in cardiac surgery patients before surgery
Debiopharm reveals phase 1/2 GaLuCi research results
The multi-centre international clinical trial will evaluate company’s Debio 0328 candidate
Ono and Macomics join forces to develop cancer therapy
The partnership will involve progressing macrophage-targeting antibody treatment for cancer
Recommendation from NICE for PTC Therapeutics gene therapy
Eladocagene exuparvovec is for children with ultra-rare genetic disorder in final draft guidance
